Quantitative in situ hybridization techniques were used to compare relative cellular levels of choline acetyltransferase (ChAT) mRNA in different regions of the female rat basal forebrain at different stages of the estrous cycle and at different time points after the administration of physiological levels of estrogen and progesterone.
Quantitative in situ hybridization techniques were used to compare relative cellular levels of choline acetyltransferase (ChAT) mRNA in different regions of the female rat basal forebrain at different stages of the estrous cycle and at different time points after the administration of physiological levels of estrogen and progesterone.
Significant fluctuations in relative levels of ChAT mRNA were detected during the course of the estrous cycle. In the medial septum (MS) and striatum, the highest levels of ChAT mRNA were detected on diestrus 1. Fluctuations in the nucleus basalis magnocellularis (NBM) were highly variable, with the highest levels detected on diestrus 2. In ovariectomized animals, significant increases in ChAT mRNA were detected in the MS, NBM, and striatum within l-3 d after a single administration of estradiol. In addition, the effects of estradiol on ChAT mRNA expression in the NBM and striatum were significantly enhanced by the subsequent administration of progesterone. The magnitude and timing of the effects of steroid replacement were consistent with the magnitude and time course of the fluctuations detected during the course of the estrous cycle. These data demonstrate that estrogen and progesterone can increase basal forebrain levels of ChAT mRNA significantly in specific regions of the rat basal forebrain, that the magnitude and time course of the effects vary between different subpopulations of cholinergic neurons, and that the effects are associated with changes in the functioning of specific basal forebrain cholinergic neurons across the estrous cycle.
Key words: cholinergic neurons; ChAT mRNA; gonadal hormones; Alzheimer's disease; estrous cycle; hormone replacement Cholinergic neurons in the basal forebrain provide the major source of cholinergic innervation to the hippocampal formation and cortex and play an important role in cortical arousal, attention, and learning and memory processes (for review, see Beninger et al., 1989; Gibbs, 1994) . Agents and/or injuries that disrupt basal forebrain cholinergic projections produce significant learning and memory deficits in both animals and humans (Drachman, 1977; Penetar and McDonough, 1983; Aigner and Mishkin, 1986; Dekker et al., 1991) . Likewise, significant cholinergic deficits associated with aging and with neurodegenerative diseases such as Alzheimer's disease and Down's syndrome have been described and are thought to contribute to both age-and diseaserelated cognitive decline.
The mechanisms responsible for the decreases in cholinergic function associated with aging and disease are currently unknown. A number of factors that can influence the survival and function of basal forebrain cholinergic neurons have been identified. Most notable are the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), which are produced in the target areas of basal forebrain cholinergic projection neurons (i.e., the hippocampus and cortex) and within subregions of the basal forebrain, and which support and enhance the survival and function of basal forebrain cholinergic neurons during development and in adulthood (for review, see Gibbs, 1994) .
Several recent studies suggest that basal forebrain cholinergic neurons also can be affected by changes in circulating levels of gonadal steroids. In particular, estrogen replaccmcnt increases choline acetyltransferase (ChAT) activity (Luine, 198.5; Singh et al., 1994) and high-affinity choline uptake (Singh et al., 1994) in the hippocampal formation, cortex, and basal forebrain of ovariectomized female rats. Estrogen replacement also incrcascs the numbers of ChAT-immunoreactive neurons detected in the medial septum (MS) and the vertical limb of the diagonal band of Broca (DBB) (Gibbs and Pfaff, 1992) and increases relative cellular levels of ChAT mRNA within cholinergic neurons located in the MS and nucleus basalis magnocellularis (NBM) (Gibbs et al., 1994) . These studies suggest that a loss of gonadal function in women contributes to a decrease in basal forebrain cholinergic function and that this effect may be reversible with appropriate hormone-replacement therapy. This idea is consistent with several recent reports showing beneficial effects of short-and long-term estrogen administration on cognitive performance in women with Alzheimer's disease (Henderson et al., 1994; Ohkura et al., 1994a Ohkura et al., ,b, 1995 .
At present, there is very little information regarding how cholinergic neurons located in different regions of the basal forebrain respond to physiological fluctuations in circulating levels of gonadal steroids. In the present study, quantitative in situ hybridization techniques were used to determine whether relative cellular levels of ChAT mRNA in different regions of the rat basal forebrain fluctuate during the course of the estrous cycle. Identical techniques also were used to examine changes in relative levels of ChAT mRNA in ovariectomized animals killed at different of diestrus 2 (n = 7) the morning of proestrus (n = 6) the afternoon (3:30-5:00 P.M.) of proestrus (n = 5), the morning of estrus (n = 6), or the morning of diestrus 1 (n = 8).
Ovariectomized animals received a single injection of 17-P-estradiol (IO Fg in 0. I ml of sesame oil, s.c.; n = 29) at 10 A.M.. Estrogen-treated animals were killed 5 hr (n = 4), 24 hr (n = 5) 53 hr (n = 5). or 72 hr (n = 5) later. In addition, IO animals received progesterone (500 pg in 0.1 ml of sesame oil, s.c.) 48 hr after receiving estrogen and were killed 5 hr (ES3+P:
)I = 5) or 24 hr fE72+P: 11 = 5) later. Ovariectomized vehicletreated animals (n = 8) were used as controls.
Tissue collecrion. Animals were anesthetized with pentobarbital (50 mgikg) and then decapitated.
The brains were removed, frozen with dry ice, and stored in liquid NZ until sectioning.
Trunk blood was collected into I6 X 125 mm' glass tubes, placed on ice for 30-60 min. and then centrifuged at 3000 X g for 20 min; the serum was collected and stored at ~20°C for the determination of estradiol circulating levels (see below). ChAT mRNA was detected using a single-stranded RNA probe prepared from a T3m transcription vector containing a highly conserved region (Sucl-HincII digest, nucleotides 1324-2044) of the rat ChAT gene (Brice et al., 1989) cloned into pBluescript.
First, the insert was subcloned and amplified with the T3 and T7 promoters intact, using PCR techniques and primers directed against the T3 and T7 promoters.
Sense and antisense riboprobes (specific activity, -2 x 10' cpmipmol) then were transcribed. using T3 and T7 RNA oolvmerases with "P-labeled uridine . , triphosphate (DuPont NEN, Boston, MA) (-800 Ciimmol) in the reaction mixture.
The probes then were hydrolyzed to an average length of -300 bases (Cox et al., 1983 Cells in the vertical limb of the DBB were omitted from the analysis because of the possibility for contamination with cells in the HDB (the horizontal limb merges with and is indistinguishable from the vertical limb at levels where the vertical limb is easily distinguished from the MS). Because of the large number of sections involved, sections were divided into experimental runs in which at least one section per animal through a given brain region was exposed to the same antisense probe within each run.
/tz s&r hybridization was performed almost exactly as described previously (Gibbs et al., 1994) . Briefly, all sections were covered with prehybridization buffer (Gibbs and Pfaff, 1994) for 2-3 hr and then with hybridization buffer (HB) (Gibbs and Pfaff, lYY4) containing '.'P-labeled sense or antisense probes (0.0X-0.1 pmolisection in 40 ~1 of HB). The sense probe was used as a negative control because it is chemically similar to the antisense probe and contains the same percentage GTP/CTP but does not bind with any known species of RNA. Some sections were hybridized with HB alone (without probe) as an additional negative control.
Hybridization proceeded for 2 d at 50°C after which sections were rinsed with 2X, 1 X, and 0.5X SSC (15 min each) and then with 0. I X SSC for 2 hr. Sections then were treated with ribonuclease A (RNasc-A Sigma type X-A: 5.0 pgiml in 10 mM Tris, pH 8.0,0.5 M NaCI, and 1 mM EDTA; St. Louis, MO) for 30 min at 37°C. rinsed with RNase butfer (30 min at 37°C) and then rinsed with 0.1 X SSC for 1 hr at 60°C followed by 0. IX SSC at 42°C overnight.
The pg/ml at 5 hr, 37.3 + 8.7 pg/ml at 24 hr, 44.6 -C 5.6 pg/ml at 53 hr, and <lo pg/ml at 72 hr after injection.
Photomicrographs showing the distribution of ChAT mRNAcontaining cells detected in the MS, HDB, NBM, and striatum as seen under low-power, dark-field illumination are shown in Figure  1 . Note the distribution of the labeled cells in each of the four regions analyzed. Examples of labeled cells as seen under higherpower, bright-field illumination are shown in Figure 2 . Note the high numbers of silver grains overlying labeled cells compared with the low numbers of grains in surrounding regions. No labeled cells were detected in sections hybridized with the sense (control) probe or with buffer alone (not shown).
Relative cellular levels of ChAT mRNA in the MS, HDB, NBM, and striatum at different stages of the estrous cycle are summarized in Figure 3 . Significant fluctuations in relative levels of ChAT mRNA were detected in the MS (F = 3.1,~ = 0.03) and the striatum (F = 3.5,~ = 0.02). The maximum percent fluctuation (peak-trough) during the estrous cycle was 24.6 and 26.9% in the MS and striatum, respectively. In both regions, the highest levels of ChAT mRNA were detected on diestrus 1. In the NBM, the maximum percent fluctuation in the relative levels of ChAT mRNA was 21.1%, with the highest levels detected on diestrus 2; however, this difference was not statistically significant (F = 1.0,~ = 0.41). In the HDB, relative levels of ChAT mRNA fluctuated a maximum of ll.l%, which was not statistically significant (F = 0.3,p = 0.86).
The effects of hormone treatment on ChAT mRNA expression are summarized in Figure 4 . Hormone treatments caused significant changes in relative cellular levels of ChAT mRNA in the MS (F = 3.9,~ = O.Ol), NBM (F = 6.5,~ < O.OOl), and striatum (F = 4.6,~ < O.Ol), but not in the HDB (F = 1.1,~ = 0.34). In the MS, a significant increase in ChAT mRNA was detected at 24 hr (22.0% & 2.0,~ < O.Ol), 53 hr (14.8% + 5.4,~ = 0.03), and 72 hr (15.1% + 6.0,~ < 0.03) after estrogen administration compared with ovariectomized controls. Subsequent administration of progesterone had no additional effect; differences between estrogentreated and estrogen plus progesterone-treated animals at 53 and 72 hr were not statistically significant. In the NBM, a significant increase in ChAT mRNA was detected at 72 hr (22.8% + 5.0,~ < 0.01) after estrogen administration. Administration of progesterone appeared to accelerate this effect such that animals that received progesterone 48 hr after receiving estrogen showed significant elevations in ChAT mRNA 5 hr later (E53+P) compared with both ovariectomized controls (27.9% -+ 3.1, p < 0.01) and animals that had received estrogen alone (E53; p = 0.02). No significant difference was detected between estrogen-treated and estrogen plus progesterone-treated animals at 72 hr after estrogen administration.
In the striatum, a significant increase in ChAT mRNA was detected as early as 5 hr after (17.5% t 5.1,~ < 0.01) but not at 24, 53, or 72 hr after receiving estrogen alone. Significant increases were detected, however, at 5 hr (E53+P; 20.4% -t 2.3,~ < 0.01) and 24 hr (E72+P; 15.9% 5 3.5,~ < 0.01) after the subsequent administration of progesterone compared with ovariectomized controls.
DISCUSSION
The data demonstrate that levels of ChAT mRNA within discrete subregions of the basal forebrain fluctuate in accordance with physiological changes in the levels of estrogen and progesterone during the course of the estrous cycle and in response to acute hormone replacement. Of particular note are the following findings. (1) Estrogen administration had different effects on different subsets of basal forebrain cholinergic neurons (no effect in the HDB, a rapid but short-lived effect in the striatum, and delayed and longer-lasting effects in the MS and NBM). (2) Effects in some areas were preceded by a 24-48 hr delay and persisted even after estrogen levels had declined significantly. (3) Progesterone significantly enhanced the effects of estrogen at specific time points in some regions. For example, in the MS, significant upregulation (22.0%) of ChAT mRNA was detected at 24 hr, but not at 5 hr, after estrogen administration and then was maintained for an additional 48 hr regardless of progesterone administration.
This was observed despite the fact that levels of circulating estradiol were highest at 5 hr and had decreased significantly by 72 hr after injection. In the NBM, significant upregulation (22.8%) of ChAT mRNA was not detected until 72 hr after estrogen administration, at a time when circulating levels of estrogen were significantly decreased. A comparable effect (27.9%) was observed earlier, however, when progesterone was administered 48 hr after estrogen treatment and the animals were processed 5 hr later. The effect of estrogen plus progesterone then was maintained such that no difference between progesteroneand non-progesteronetreated animals was detected at 72 hr after estrogen treatment. In the striatum, significant upregulation (17.5%) of ChAT mRNA was detected as early as 5 hr after estrogen administration but declined rapidly such that no significant effect was detected 24,53, or 72 after receiving estrogen alone. A significant increase in ChAT mRNA was detected again 5 hr (20.2%) and 24 hr (15.9%) after the administration of progesterone, however, which suggests that progesterone can enhance and prolong the effects of estrogen on ChAT mRNA expression in the striatum. Note that these effects are consistent with previous reports showing significant increases in the numbers of ChAT-like immunoreactive cells in the MS and VDB (but not the HDB), and significant increases in ChAT mRNA in the MS and NBM (but not the HDB), after longer-term continuous estrogen administration (Gibbs and Pfaff, 1992; Gibbs et al., 1994) .
The effects of hormone replacement were consistent for the most part with the fluctuations in ChAT mRNA detected in each subregion of the basal forebrain during the course of the estrous cycle. For example, no significant fluctuation in the level of ChAT mRNA was detected in the HDB. In the MS, relative levels of ChAT mRNA increased after proestrus and peaked on diestrus 1, nearly 2 d after peak levels of circulating estrogen. This is consistent with the 24 hr delay between estrogen administration and changes in ChAT mRNA in the MS described above. Likewise, in the NBM the highest levels of ChAT mRNA were detected on diestrus 2, which is consistent with the 2-3 d delay between hormone administration and the changes in ChAT mRNA detected in the NBM. Although fluctuation in the NBM across the estrous cycle did not reach statistical significance, maximal fluctuation was 19.2%, which is close to the changes of 22.8 and 21.8% detected 72 hr after the administration of estrogen and estrogen plus progesterone. It is likely that the relatively long lag time of 3 d for the estrogen effect compounded by preparation for entry into another cycle added significant variation to the data, making fluctuations in the NBM of cycling animals more difficult to detect. In the striatum, the highest levels of ChAT mRNA were detected on diestrus 1, which is consistent with the effects of estrogen and progesterone administration on ChAT mRNA detected in the striatum.
Taken together, these data indicate that levels of ChAT mRNA in the MS, NBM, and striatum fluctuate significantly in response to changes in physiological levels of circulating gonadal steroids. Why a significant elevation in ChAT mRNA was not detected in the striatum on the morning of estrus is still unclear. One possibility is that rapid changes occur between the afternoon of proestrus and the morning of estrus at a time point not included in our sampling. Another possibility is that the cells are exposed to estrogen for a minimum length of time before a significant upregulation of ChAT mRNA by progesterone can be produced. This would be consistent with a need for estrogen-induced upregulation of progesterone receptors in these cells before a progesterone effect is elicited. Whether basal forebrain cholinergic neurons express progesterone receptors and whether those receptors are regulated by physiological changes in circulating estrogen are still unclear. At least one previous study failed to detect basal or estrogen-induced progesterone receptors in the MS, DBB, and caudate-putamen (Parsons et al., 1982) . Evidence for membranemediated effects of progesterone and progesterone metabolites have been described, particularly with respect to interactions with the GABA,-receptor complex and GABA,-mediated transmission (Robe] and Baulieu, 1994). Local infusions of GABA or the GABA,-receptor agonist muscimol produce significant reductions in the levels of ACh release in different areas of cortex (Wood and Richard, 1982; Casamenti et al., 1986) . Selective impairments in memory performance after injections of muscimol into the NBM also have been described (Beninger et al., 1992) . Clearly, the possibility that effects of progesterone on basal forebrain cholinergic neurons are related to effects on GABAergic transmission needs to be explored.
The mechanisms by which estrogen influences ChAT mRNA expression in basal forebrain cholinergic neurons remain unclear. Toran-Allerand et al. (1992) reported the presence of high-affinity estrogen-binding sites within NGF receptor-containing cells located in the MS and DBB. Likewise, we have recently detected the presence of estrogen receptor-like immunoreactivity within significant numbers of cholinergic neurons located in the MS, HDB, NBM, and striatum of gonadectomized rats (unpublished observations), providing a potential mechanism for direct estrogen effects on the cholinergic neurons. One possibility is that estrogen directly upregulates expression of the ChAT gene within specific cholinergic cells. This may be the case in the striatum, where a
ChAT mRNA expression at specific time points. The extent to significant increase in ChAT mRNA was detected as early as 5 hr which these effects are mediated via direct hormone effects on after estrogen administration.
Another possibility is that estrogen basal forebrain cholinergic neurons needs to be assessed. increases the half-life of ChAT mRNA inside the cell [comparable with the effects of estrogen on vitellogenin mRNA (Brock and Shapiro, 1983) ], causing a gradual increase in ChAT mRNA over time. This could account for the rather long delay between estrogen administration and the effects on ChAT mRNA detected in the MS and NBM. It also could account for the fact that increases in ChAT mRNA in the MS and NBM persist well after estrogen levels have returned to baseline. Neither explanation fully accounts for the differences in the effects of estrogen and progesterone on cholinergic neurons located in different regions of the basal forebrain.
Other possibilities include indirect effects of estrogen mediated via other transmitter systems, growth factors, and growth-factor receptors that are known to influence basal forebrain cholinergic neurons directly. GABAergic and monoaminergic (noradrenalin and serotonin) effects on cholinergic neurons in the MS, DBB, and NBM have been described (for review, see Decker and McGaugh, 1991) , and they may be influenced by estrogen administration. NGF and BDNF are present in the targets of cholinergic projection neurons, and both exert trophic effects on cholinergic neurons located in the MS, DBB, NBM, and striatum (Lapchak and Hefti, 1992; Morse et al., 1993; Emmett et al., 1995) . NGF, in particular, upregulates ChAT mRNA, ChAT activity, high-affinity choline uptake, and ACh production and release within basal forebrain cholinergic neurons projecting to the hippocampal formation and cortex (for review, see Gibbs, 1994) . The effects of the neurotrophins are mediated by binding to specific transmembrane receptors, including the low-affinity neurotrophin receptor (p75NGFR) and tyrosine kinase receptors specific for NGF (TrkA) and BDNF (TrkB) (Barbacid, 1993) . Singh et al. (1995) reported significant elevations in hippocampal and cortical levels of BDNF mRNA after estrogen administration in rats. Effects of estrogen on relative levels of NGF mRNA also have been described, and both increases (Singh et al., 1993) and decreases (Gibbs et al., 1994) were reported. Gibbs and coworkers reported significant decreases in p75NGFR mRNA and protein (Gibbs and Pfaff, 1992) as well as decreases in TrkA mRNA (Gibbs et al., 1994) in the MS and NBM after longer-term (2-6 weeks), continuous estrogen replacement. These data demonstrate that estrogen administration can have significant effects on growth factors and growth-factor receptors which, in turn, could influence ChAT expression within basal forebrain cholinergic neurons. Such an indirect mechanism could explain the rather long lag time between estrogen administration and effects on ChAT mRNA in the MS and NBM. It could also explain why no effects were detected in the HDB, as in previous reports (Gibbs and Pfaff, 1992; Gibbs et al., 1994) , because cholinergic neurons in the HDB project primarily to the olfactory bulb, whereas those in the MS and NBM project primarily to the hippocampal formation and cortex. Whether similar effects occur in response to different dosages and regimens of estrogen treatment, and whether the effect that these changes have on the sensitivity of basal forebrain cholinergic neurons to specific growth factors, still needs to be determined.
In conclusion, these data indicate that physiological changes in circulating levels of estrogen can significantly affect relative levels of ChAT mRNA in the MS, NBM, and striatum of adult female rats. The data also indicate that subsequent administration of progesterone can significantly enhance the effects of estrogen on
